[{"id":"da5af055-0246-4668-a44a-63ea071d356a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07158710","created_at":"2025-09-13T08:45:39.340Z","updated_at":"2025-09-13T08:45:39.340Z","phase":"Phase 1","brief_title":"Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation","source_id_and_acronym":"NCT07158710","lead_sponsor":"Haisco Pharmaceutical Group Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 05/23/2029","primary_completion_date":" 05/23/2029","study_txt":" Completion: 12/03/2029","study_completion_date":" 12/03/2029","last_update_posted":"2025-09-08"},{"id":"415c095a-fdbb-4c01-9393-539ef53dc7d9","acronym":"SuRage-EB","url":"https://clinicaltrials.gov/study/NCT07092410","created_at":"2025-08-02T14:07:29.999Z","updated_at":"2025-08-02T14:07:29.999Z","phase":"Phase 4","brief_title":"Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib","source_id_and_acronym":"NCT07092410 - SuRage-EB","lead_sponsor":"SRH Wald-Klinikum Gera GmbH","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 101","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 08/01/2030","primary_completion_date":" 08/01/2030","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-07-29"},{"id":"1b1049ad-72e3-482d-a433-13cd63e6b89e","acronym":"UK-EnBiRiM","url":"https://clinicaltrials.gov/study/NCT07022457","created_at":"2025-06-21T13:21:55.578Z","updated_at":"2025-06-21T13:21:55.578Z","phase":"","brief_title":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","source_id_and_acronym":"NCT07022457 - UK-EnBiRiM","lead_sponsor":"Vitaccess Ltd","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/23/2025","start_date":" 06/23/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 12/06/2027","study_completion_date":" 12/06/2027","last_update_posted":"2025-06-15"},{"id":"9477387b-6d4d-44dc-94ca-1342835e5367","acronym":"BREAKWATER","url":"https://clinicaltrials.gov/study/NCT04607421","created_at":"2021-01-19T20:31:44.383Z","updated_at":"2025-02-25T13:53:29.320Z","phase":"Phase 3","brief_title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04607421 - BREAKWATER","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 823","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/06/2025","primary_completion_date":" 01/06/2025","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-20"},{"id":"2223e62c-2304-4f09-b793-71e2fb24f5a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03224767","created_at":"2021-04-28T13:53:13.407Z","updated_at":"2025-02-25T14:15:02.976Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma","source_id_and_acronym":"NCT03224767","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-18"},{"id":"0e6f9786-f03c-47e3-82a4-50892d86b673","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102902","created_at":"2023-10-26T15:14:21.567Z","updated_at":"2025-02-25T14:10:15.325Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","source_id_and_acronym":"NCT06102902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/05/2024","start_date":" 06/05/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"d494a72a-9ff2-45f5-b7e1-6d9a0c5e5875","acronym":"","url":"https://clinicaltrials.gov/study/NCT05503797","created_at":"2022-08-17T14:55:09.900Z","updated_at":"2025-02-25T14:09:04.053Z","phase":"Phase 2","brief_title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","source_id_and_acronym":"NCT05503797","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/27/2025","primary_completion_date":" 06/27/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-17"},{"id":"37a71962-26f2-4826-b060-0159d0866f3c","acronym":"ECLYPse","url":"https://clinicaltrials.gov/study/NCT06640166","created_at":"2025-02-25T15:22:11.847Z","updated_at":"2025-02-25T15:22:11.847Z","phase":"Phase 2","brief_title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","source_id_and_acronym":"NCT06640166 - ECLYPse","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/03/2024","start_date":" 06/03/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"152d28df-5166-4844-8189-63865407b89e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954546","created_at":"2023-07-20T23:10:56.186Z","updated_at":"2025-02-25T16:46:55.104Z","phase":"","brief_title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings","source_id_and_acronym":"NCT05954546","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-05"},{"id":"d0abf381-bbfa-4b21-bbe7-740e5caad62b","acronym":"BEAVER","url":"https://clinicaltrials.gov/study/NCT03839342","created_at":"2021-01-18T18:57:15.711Z","updated_at":"2025-02-25T16:59:56.947Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","source_id_and_acronym":"NCT03839342 - BEAVER","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF mutation • BRAF V600K • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600K • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"5b5025e1-918a-44f3-b1e4-127e110ec295","acronym":"","url":"https://clinicaltrials.gov/study/NCT05026983","created_at":"2021-08-30T21:53:02.254Z","updated_at":"2025-02-25T17:30:53.797Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","source_id_and_acronym":"NCT05026983","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-30"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"c022581a-a340-436e-b4e7-18bfc5a946d3","acronym":"BRICKET","url":"https://clinicaltrials.gov/study/NCT06578559","created_at":"2025-02-25T16:02:55.886Z","updated_at":"2025-02-25T16:02:55.886Z","phase":"Phase 2","brief_title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","source_id_and_acronym":"NCT06578559 - BRICKET","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-01-23"},{"id":"72272cbc-c9f7-4112-ac79-128d9c683b5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06610682","created_at":"2025-02-26T07:01:00.356Z","updated_at":"2025-02-26T07:01:00.356Z","phase":"Phase 1","brief_title":"Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib","source_id_and_acronym":"NCT06610682","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-01-13"},{"id":"ad4f690b-b51c-4f70-aa01-5da5b0887bb4","acronym":"CEBBRA","url":"https://clinicaltrials.gov/study/NCT06207656","created_at":"2024-01-17T16:18:48.040Z","updated_at":"2025-02-25T16:11:23.465Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","source_id_and_acronym":"NCT06207656 - CEBBRA","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-10-21"},{"id":"e654c874-ff26-4818-92d4-ab360c653d3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068752","created_at":"2021-10-06T12:53:53.320Z","updated_at":"2025-02-25T17:25:17.327Z","phase":"Phase 2","brief_title":"Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer","source_id_and_acronym":"NCT05068752","lead_sponsor":"HonorHealth Research Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • sorafenib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-09-19"},{"id":"250adcfc-f0cd-41e1-858f-4eaad0c4215c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536400","created_at":"2025-02-27T08:00:06.313Z","updated_at":"2025-02-27T08:00:06.313Z","phase":"Phase 1","brief_title":"Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation","source_id_and_acronym":"NCT06536400","lead_sponsor":"Haisco Pharmaceutical Group Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/25/2024","start_date":" 06/25/2024","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 07/07/2027","study_completion_date":" 07/07/2027","last_update_posted":"2024-08-05"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"0c9f5f05-6df2-4534-8291-c2ac3324cb6a","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT02304809","created_at":"2021-01-17T17:46:46.183Z","updated_at":"2024-07-02T16:34:37.044Z","phase":"Phase 2","brief_title":"Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","source_id_and_acronym":"NCT02304809 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 10/13/2014","start_date":" 10/13/2014","primary_txt":" Primary completion: 05/07/2019","primary_completion_date":" 05/07/2019","study_txt":" Completion: 10/13/2027","study_completion_date":" 10/13/2027","last_update_posted":"2024-06-07"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"db82afaa-1da0-4791-94e2-92a3b0bc6788","acronym":"BECOME-MB","url":"https://clinicaltrials.gov/study/NCT04074096","created_at":"2021-01-18T19:57:18.686Z","updated_at":"2025-02-25T16:09:27.668Z","phase":"Phase 2","brief_title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","source_id_and_acronym":"NCT04074096 - BECOME-MB","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2022","start_date":" 09/05/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2029","study_completion_date":" 04/15/2029","last_update_posted":"2024-06-03"},{"id":"b30b1e44-f866-4d50-98ee-25a4b13b78d0","acronym":"ImmunoCobiVem","url":"https://clinicaltrials.gov/study/NCT02902029","created_at":"2021-03-22T16:53:54.040Z","updated_at":"2024-07-02T16:35:01.852Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","source_id_and_acronym":"NCT02902029 - ImmunoCobiVem","lead_sponsor":"University Hospital, Essen","biomarkers":" PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-05-23"}]